Alliancebernstein L.P. Actinium Pharmaceuticals, Inc. Transaction History
Alliancebernstein L.P.
- $287 Billion
- Q3 2024
A detailed history of Alliancebernstein L.P. transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 13,890 shares of ATNM stock, worth $18,473. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,890
Previous 13,890
-0.0%
Holding current value
$18,473
Previous $102,000
74.51%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ATNM
# of Institutions
77Shares Held
8.35MCall Options Held
65.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$2.16 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA686KShares$912,5830.0% of portfolio
-
State Street Corp Boston, MA603KShares$801,5230.0% of portfolio
-
Acadian Asset Management LLC Boston, MA454KShares$603,4130.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $33.5M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...